selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Their most advanced drug candidate is si-544 which is a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.The company is well positioned t... Read more